louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06108973: Evaluation of Consumption of Sevoflurane in Chronic Obstructive Pulmonary Disease Patients
Official title: Evaluation of Consumption of Sevoflurane in Chronic Obstructive Pulmonary Disease Patients Under General Anesthesia
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Chronic Obstructive Pulmonary Disease
Lead sponsor: Employee's State Insurance Corporation, New Delhi
Sponsor class: OTHER_GOV
Collaborators: name: Medtronic Spine LLC
First posted: 2023-10-31
Enrollment: 45
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Geography South East Asia-Sothern Peninsular INDIA'

Soci Economic Mid Earning

Brief summary: All the Patients undergoing General Anesthesia and the patients who are having Chronic Obstructive Pulmonary Disease will be considered for this study. The Volume consumption of Sevoflurane will be studied in accordance with age, sex, duration , type of surgery, site of surgery and BMI.The volume consumption of sevoflurane is compared with Chronic Obstructive Pulmonary Disease and Normal Patients .

Detailed description: Chronic Obstructive pulmonary disease is known to escalate the consumption of Inhalation Agents in General Anesthesia. Hence the Data to Collect the Official Record

Eligibility criteria: Inclusion Criteria:

* Both Sex All Age Group Patient willing to give consent COPD patient

Exclusion Criteria:

* Not willing to give consent Cancerous Lung Lung Lobectomy

Primary outcomes:
measure: Estimation of Volume consumption of Sevoflurane
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: ESIC
name: Dr Manjunath, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01685073: The Role of Sleep in the Treatment of Cannabis Use Disorders
Official title: The Role of Sleep in the Treatment of Cannabis Use Disorders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Drug Addiction
Keywords: marijuana
cannabis
treatment
insomnia
relapse
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2012-09-13
Enrollment: 127
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The number of people seeking treatment for marijuana-related problems is on the rise, yet there is no currently accepted medication proven to help them quit. Frequent marijuana users have reported that they have trouble sleeping when they try to quit, and that the loss of sleep can lead to relapse. This research is designed to measure the severity of sleep problems in people as they are trying to quit heavy use of marijuana, and to investigate whether extended-release zolpidem (Ambien CR®) can improve quit rates among people trying to stop using marijuana.


Eligibility criteria: Inclusion Criteria:

1. Age 18-55 years.
2. Recent problematic use of cannabis
3. Cannabis use impacts sleep

Exclusion Criteria:

1. Dependent on drugs other than cannabis or nicotine, or current Axis I psychiatric disorder
2. Moderate sleep apnea or periodic limb movement disorder
3. Pregnant, breast feeding, or planning to become pregnant within the next 3 months
4. Current condition associated with severe cognitive/social impairment
5. Allergy to any ingredient in extended-release zolpidem or prior adverse reaction to zolpidem
6. Current use of drugs that affect metabolism via cytochrome P450 or current illness resulting in severe hepatic impairment
7. Current use of hypnotic medications

Primary outcomes:
measure: Sleep Efficiency as Assessed by Percentage of Time Asleep While in Bed
timeFrame: Week 1 of treatment
measure: Number of Participants With Cannabis Abstinence as Assessed by Urine Cannabis Testing
timeFrame: Week 12
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins University
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Ryan Vandrey, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Pacek LR, Herrmann ES, Smith MT, Vandrey R. Sleep continuity, architecture and quality among treatment-seeking cannabis users: An in-home, unattended polysomnographic study. Exp Clin Psychopharmacol. 2017 Aug;25(4):295-302. doi: 10.1037/pha0000126.
Clinical trial NCT02643173: Hepatocellular Carcinoma Recurrence and Anesthesia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatocellular Carcinoma
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2015-12-31
Enrollment: 259
Sex: ALL
Minimum age (years): 20
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing surgery due to the HCC.

Brief summary: The investigators will verify the prognosis of hepatocellular carcinoma (HCC) according to the main anesthetic agents used for the general anesthesia.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing surgery due to the HCC.

Exclusion Criteria:

* Patients undergoing re-operation due to the HCC.
* Patients presenting distant metastasis.
* Patients undergoing liver transplantation surgery.

Primary outcomes:
measure: Recurrence of HCC
timeFrame: Postoperative 2 year
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi
Study officials:
References:
Clinical trial NCT03237273: HEAD-US SCORING SYSTEM: Assessment of the Real-world Impact of Ultrasound
Official title: HEAD-US SCORING SYSTEM: Assessment of the Real-world Impact of Ultrasound on Disease Management and Treatment Decision-making in Moderate and Severe Haemophilia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Moderate and Severe Haemophilia
Lead sponsor: Guy's and St Thomas' NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2017-08-02
Enrollment: 200
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Ultrasound represents a promising technique for the assessment of joint health in persons with haemophilia (PWH) by non-imaging specialists. The Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) programme has been developed with the aim of integrating joint ultrasound in the routine assessment of PWH through the use of a simplified scoring system. The inter-operator reliability of the technique among European haemophilia treaters has been validated and described elsewhere. Further work is needed to assess the real-world impact of ultrasound on disease management and treatment decision-making.

Detailed description: Patients are seen routinely in clinic by specialist haemophilia physiotherapists who assess the patients using the Haemophilia Joint Health Score tool (HJHS). Trial participants will be seen during their routine clinic visits and will be seen by a clinician and the physiotherapist who will carry out the routine assessment along with the HEAD-US scan.

Patients will be seen a maximum of 4 times throughout the year from registration of the first patient, according to their visit schedule, but will only be scanned at the first visit.

Results will be analysed to determine if the treatment decision-making is influenced by the results of the scan

Eligibility criteria: Inclusion Criteria:

* Moderate (FVIII/FIX:C 1-5%) and severe (FVIII/FIX: C \<1%) patients with haemophilia A or B aged ≥ 6 years
* On demand or prophylaxis treatment regimen

Exclusion Criteria:

* Joints with a previous history of surgery
* Joints with damage as a result of causes other than haemophilia-related bleeding

Primary outcomes:
measure: Any change in treatment
timeFrame: 12 months
Secondary outcomes:
measure: % joints with normal HJHS and abnormal HEAD-US score
timeFrame: 12 months
measure: % joints with abnormal HJHS and normal HEAD-US score
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
affiliation: Guy's and St Thomas' NHS Foundation Trust
name: Gerard Dolan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06290973: Quality of Life and Health Perception After Surgery of Varicose Veins
Official title: Quality of Life and Health Perception After Surgery of Varicose Veins
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Quality of Life
Varicose Veins
Lead sponsor: Hospital Clínico Universitario de Valladolid
Sponsor class: OTHER
First posted: 2024-03-04
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with varicose veins undergoing surgery between january and february of 2023 in Valladolid Clinical Hospital

Brief summary: The aim of this study is to analyze changes in health perception and quality of life in patients after surgery for varicose veins using clinical score VCSS and QoL scores SF12 as general health questionary and Veines QoL/Sym as disease specific questionary.


Eligibility criteria: Inclusion Criteria:

* patients with reflux in saphenous vein

Exclusion Criteria:

* no reflux in saphenous vein

Primary outcomes:
measure: changes in qol questionarie SF-12 after surgery of varicose veins
timeFrame: before and 90 days after surgery
measure: changes in qol questionarie Veines QoL/Sym after surgery of
timeFrame: before and 90 days after surgery
Secondary outcomes:
measure: changes in VCSS after surgery of varicose veins
timeFrame: before and 90 days after surgery
Other outcomes:
Locations:
city: Valladolid
country: Spain
facility: Hospital CLínico Universitario de Valladolid
Study officials:
References:
Clinical trial NCT03330873: The Efficacy and Safety of Disposable Balloon Uterine Stent in Patients With Asherman Syndrome
Official title: Randomized, Controlled Trial to Assess the Efficacy of Disposable Balloon Uterine Stent and Foley Catheter in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Intrauterine Adhesion
Keywords: Asherman syndrome
disposable balloon uterine stent
hysteroscopy
Foley catheter
Lead sponsor: Beijing Obstetrics and Gynecology Hospital
Sponsor class: OTHER
First posted: 2017-11-06
Enrollment: 80
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Asherman's syndrome is characterized by the presence of intrauterine adhesions (IUA) as well as symptoms such as amenorrhea, hypomenorrhea, pelvic pain, and infertility. The gold standard for the treatment of intrauterine adhesions is hysteroscopic intrauterine adhesions. The recurrence of intrauterine adhesions is a major challenge in clinical practice. The isolation of barriers in the uterine cavity may be a measure to reduce postoperative re adhesion, but the effect of different devices is different. Therefore, this study was conducted.

Detailed description: The Foley catheter is usually inserted into the uterine after a hysteroscopic adhesiolysis and removed after on the 5-7th day after surgery. Several investigators demonstrated its favorable effect in the recurrence of adhesion after the treatment of intrauterine adhesion. Disposable balloon uterine stent is specially designed to fit into the cavity of the uterus, and usually removed on the 7th day after surgery.

Eligibility criteria: Inclusion Criteria:

* age 20-40 years;
* Moderate to severe intrauterine adhesion (AFS score ≥5）;
* complains of menstruation disorder and reproductive dysfunction
* Agreement to have second-look hysteroscopy
* informed consent

Exclusion Criteria:

* ovarian failure
* patients who did not proceed to second-look hysteroscopy within the specified time frame
* Contraindication of hormone

Primary outcomes:
measure: second diagnostic hysteroscopy
timeFrame: Within the first 3 months after surgery
Secondary outcomes:
measure: Menstruation Pattern
timeFrame: Within the first 3 months after surgery
measure: Number of participants with pregnancy
timeFrame: one year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Obstetrics and Gynecology Hospital，Capital Medical University
state: Beijing
Study officials:
affiliation: Beijing Obstetrics and Gynecology Hospital
name: Duan Hua, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00470873: Vardenafil Treatment Of Erectile Dysfunction In Depressive And Non-Depressive Men
Official title: A Non-Interventional, Post-Marketing Surveillance Phase IV Study to Obtain Data on Safety and Efficacy of Levitra® in Routine Treatment of Erectile Dysfunction in Depressive and Non-Depressive Men.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Erectile Dysfunction
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2007-05-08
Enrollment: 2471
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil

Brief summary: The primary aim of this open, uncontrolled, prospective, non-interventional post-marketing surveillance study is to obtain data on safety and efficacy of Levitra in routine treatment of erectile dysfunction. The secondary aim of this study is to assess the influence of the treatment with Levitra on self-esteem (depressive symptomology) in men with ED.


Eligibility criteria: Inclusion Criteria:

* Age over 18
* Erectile dysfunction untreated or ineffectively treated with other than vardenafil PDE5 inhibitors

Exclusion Criteria:

* Treatment with nitrates
* Allergy to vardenafil or other tablets ingredients
* Treatment with CYP3A4 inhibitors (e.g. indinavir, ritonavir, ketoconazole, itraconazole, erythromycin)
* Cardiovascular status excluding any sexual activity

Primary outcomes:
measure: Efficacy, safety, tolerance of the treatment with Vardenafil reported by the physician
timeFrame: At the patients control visit (approx. 3 months from the initial)
Secondary outcomes:
measure: Influence of vardenafil on depressive symptoms and self-esteem measured with CES-D and Rosenberg scale
timeFrame: At the patients control visit (approx. 3 months from the initial)
Other outcomes:
Locations:
city: Many locations
country: Poland
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01306773: Convalescent Plasma Treatment in Severe 2009 H1N1 Infection
Official title: Convalescent Plasma Treatment in Patients With Severe 2009 H1N1 Infection: a Prospective Cohort Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Influenza A
Keywords: Influenza A
convalescent plasma
death
Lead sponsor: The University of Hong Kong
Sponsor class: OTHER
First posted: 2011-03-02
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Treatment of severe 2009 H1N1 infection with convalescent plasma will reduce mortality.

Detailed description: Patients presented with severe 2009 H1N1 infection responded poorly to antiviral agents. Meta-analysis of reports from 1918 H1N1 pandemic suggested that convalescent plasma might be an effective treatment option for patients with severe 2009 H1N1 infection.

Eligibility criteria: Inclusion Criteria:

* adult patients ≥ 18 years old with written informed consent given by patient or next-of-kin
* laboratory confirmatory diagnosis of 2009 H1N1 infection by positive RT-PCR from respiratory specimens
* required intensive care within 7 days of onset of symptoms

Exclusion Criteria:

* age 18 years old or below
* known hypersensitivity to immune globulin
* known IgA deficiency

Primary outcomes:
measure: Death
timeFrame: Participants are followed until death or discharge from ICU (average 2 weeks)
Secondary outcomes:
measure: Complication
timeFrame: Participants are followed until death or discharge from ICU (average 2 weeks)
measure: Length of stay in ICU
timeFrame: Participants are followed until death or discharge from ICU (average 2 weeks)
measure: Adverse events secondary to the convalescent plasma treatment
timeFrame: Participants are followed until death or discharge from ICU (average 2 weeks)
measure: Time on respiratory support
timeFrame: Participants are followed until death or discharge from ICU (average 2 weeks)
measure: Change in viral load
timeFrame: Participants are followed until death or discharge from ICU (average 2 weeks)
measure: Change in cytokine level
timeFrame: Participants are followed until death or discharge from ICU (average 2 weeks)
Other outcomes:
Locations:
city: Hong Kong SAR
country: China
facility: The University of Hong Kong, Queen Mary Hospital
Study officials:
affiliation: The University of Hong Kong
name: Ivan FN HUNG, MD FRCP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06038773: Social and Clinical Aspects of Pelvic Pain in Turkey
Official title: Social and Clinical Aspects of Pelvic Pain in Turkey
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Pelvic Pain Syndrome
Lead sponsor: Yeditepe University
Sponsor class: OTHER
First posted: 2023-09-15
Enrollment: 45
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study included 45 women with pelvic pain. Women aged 18-65 years with pelvic pain ≥6 months were eligible. The study was conducted at Yeditepe University Hospital on female patients diagnosed with chronic pelvic pain syndrome due to pelvic floor muscle problems by a gynecologist.

Brief summary: Chronic Pelvic Pain (CPP) is a common medical condition with a complex treatment due to different variables that influence its clinical course.There is a growing literature which discussing the effect of ethnicity and culture on pain. It was aimed to invesitigate whether there is a considerable difference in the presentation and experience of pelvic pain in women from a different societies and cultures.

Detailed description: Chronic Pelvic Pain (CPP) is a common medical condition with a complex treatment due to different variables that influence its clinical course.There is a growing literature which discussing the effect of ethnicity and culture on pain. It was aimed to invesitigate whether there is a considerable difference in the presentation and experience of pelvic pain in women from a different societies and cultures.

The study includes randomly selected 45 females who completed a comprehensive set of questions derived from International Pelvic Pain Society (IPPS), pelvic pain assesment form. Character and intensity of pain, sexual abuse and harresment, coping with pain, physical activites (exercising) and comorbidities were evaluated. The McGill pain questionnaire short form was used to evaluate pain. Sexual Abuse Items in the Questionnaire (modified) to assess patients' sexual abuse status.

Eligibility criteria: Inclusion Criteria:

* Women aged 18-65 years with pelvic pain ≥6 months were eligible.

Exclusion Criteria:

* Patient who have had pelvic surgery
* Gynecological female patients with problems other than pelvic pain

Primary outcomes:
measure: McGill pain scale
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Nilüfer Cerbezer
Study officials:
affiliation: Yeditepe Üniversitesi
name: nilüfer cerbezer, Msc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02578173: Evaluation of a Novel Method of Contrast Volume Quantification - AVERT PLUS 2.0
Official title: Evaluation of a Novel Method of Contrast Volume Quantification - AVERT PLUS 2.0
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Kidney Injury
Lead sponsor: The University of Texas Health Science Center at San Antonio
Sponsor class: OTHER
First posted: 2015-10-16
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with cardiovascular disease who are undergoing clinically indicated coronary or peripheral angiography

Brief summary: Purpose: To evaluate the accuracy of the AVERT PLUS to monitor contrast volume used during angiographic procedures. This will be a first in man prospective observational study of the accuracy of this system to quantify contrast volume used during clinically indicated angiography in the cardiac catheterization laboratory.

Detailed description: Research Design:

The AVERT PLUS is an FDA 510K cleared device which consists of 1) a contrast delivery modulator designed to reduce unnecessary contract dye delivery to the patient during angiography (coronary or peripheral) and 2) a concomitant contrast monitoring system to precisely measure contrast volume delivered to the patient. This will be a first in man prospective observational study of the accuracy of this system to quantify contrast volume used during clinically indicated angiography in the cardiac catheterization laboratory.

Eligibility criteria: Inclusion Criteria:

* Patients undergoing clinically indicated coronary or peripheral angiography

Exclusion Criteria:

* None

Primary outcomes:
measure: Observational study of the accuracy of the AVERT PLUS CM system to quantify contrast volume during a clinically indicated procedure.
timeFrame: The total volume of contrast received by the subject will be measured at the conclusion of the angiography procedure, procedure duration from 30 minutes to 4 hours dependent on patient's clinical status; no further measurements thereafter.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Osprey Medical, Inc
name: Michele Shepard
role: STUDY_DIRECTOR
References:
Clinical trial NCT01107873: Changes of Dorsalis Pedis Artery Flow Pattern After Caudal Block in Children: Observational Study Using a Duplex Sonography
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anesthesia, Caudal
Keywords: Twenty (ASA status I) unpremedicated children, ages 1 to 5 yr old
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2010-04-21
Enrollment: 20
Sex: MALE
Minimum age (years): 1
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: children patients who visit Severance hospital

Brief summary: The purpose of this study is to determine the changes of Dorsalis Pedis Artery Flow Pattern after Caudal Block in Children: Observational Study Using a Duplex Sonography.


Eligibility criteria: Inclusion Criteria:

* Twenty (ASA status I) unpremedicated children, ages 1 to 5 yr old, who were scheduled for a day-case urologic surgery

Exclusion Criteria:

* if there were contraindications for caudal block including hypersensitivity to any local anaesthetics, bleeding diathesis, infections at the puncture sites, or pre-existing neurological disease.

Primary outcomes:
measure: Investigation of arterial hemodynamics
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea
name: Hae Keum Kil
role: PRINCIPAL_INVESTIGATOR
References: